This article is available to subscribers. Subscribe now. Already have an account? Sign in

Clinical PracticeFree Preview

Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes

List of authors.
  • Rita R. Kalyani, M.D.

In patients with type 2 diabetes and established cardiovascular disease (or in those with a high risk of cardiovascular disease) in whom glycemic goals are not achieved with metformin, agents from the GLP-1 receptor agonist or SGLT2 inhibitor classes with demonstrated cardiovascular benefit constitute the recommended treatment.

Funding and Disclosures

Disclosure forms provided by the author are available with the full text of this article at NEJM.org.

No potential conflict of interest relevant to this article was reported.

I thank David Cooper, M.D., Erin Michos, M.D., and Mansur Shomali, M.D., for their valuable suggestions regarding earlier versions of the manuscript.

Author Affiliations

From the Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore.

Address reprint requests to Dr. Kalyani at the Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University School of Medicine, 1830 E. Monument St., Ste. 333, Baltimore, MD 21287, or at .

Print Subscriber? Activate your online access.